Partnerships
Jennerex is a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer. We have entered into several development and commercialization alliances with partners to bring our first-in-class cancer therapeutics to patients world-wide. We have proprietary technology platforms that can generate highly targeted, oncolytic virus agents for the effective treatment of cancers. We are continually reviewing new discoveries and breakthrough technologies for in-license and collaboration opportunities. Jennerex has not yet licensed rights for JX-594 in the United States or Japan.
Corporate Partners:
Transgene
We have licensed to Transgene exclusive rights to develop and commercialize JX-594 in Europe, 
the CIS and the Middle East. Together, we will co-develop JX-594 worldwide, with Transgene responsible for development costs and for clinical development in its licensed territories, pursuant to the JX-594 global development plan. Transgene is responsible for commercialization and has the right to manufacture JX-594 in the Transgene territory. As part of this agreement Transgene has made an upfront equity investment in Jennerex, and we are further eligible to earn a total of up to $116 million in development and registration milestones as well as double digit royalties on a tiered structure. In addition, we have an option for co-promotion and profit-sharing in the five major European countries. (See press release)
Green Cross Corp.
We currently have a product development and licensing agreement for JX-594 with Green Cross (Seoul, S. Korea) for the Korean market. Together we are focused on the development and eventual commercialization of JX-594 for liver cancers and other cancer indications in the Korean market. Green Cross is a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products. (See press release)
Lee's Pharmaceuticals.
We are partnered with Lee's Pharmaceutical Holdings (HK Stock code: 8221) for JX-594 development and commercialization in China. Lee's is a public biopharmaceutical company with over 14 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets six products. (See press release)
Rex Medical
We have an alliance with Rex Medical, a manufacturer of advanced multi-pronged needles, for the use of this advanced needle for targeted intratumoral administration of JX-594. We exclusively use Rex Medical Quadra-Fuse needles ("QF Needles") for intratumoral injections of JX-594 in clinical development, and Rex Medical works collaboratively with us to effectively apply this technology to JX-594 clinical development. (See press release)
Quadra-fuse Multi-Pronged
Needle for IT Injection:
Widespread, uniform
distribution within liver tumors
SillaJen, Inc.
SillaJen is a biotechnology company established to support collaborations with us in the areas of clinical assay development and services, translational research, and GMP manufacturing for the production of oncolytic viruses. SillaJen's collaboration activities are led by Dr. Tae-Ho Hwang, our research advisor and head of Pusan Research Site. SillaJen has been a collaborator and a major investor in Jennerex since 2006.
Academic Alliances: Clinical and Discovery Research Collaborations
National Cancer Institute (Cell screening group)
National Cancer Institute of Canada (Clinical Trials Group)
University of Pittsburgh (David Bartlett, Chief of Surgery, Oncology)
Institute of Cancer Research/Royal Marsden Hospital (London, UK)
Oxford University (Dept. Clinical Pharmacology)
Ottawa Health Research Institute (Ottawa, Canada)
